Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bird Flu Expert Working on Vaccine that Protects Against Multiple Strains

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
As the bird flu outbreak in China worsens, a Purdue University expert is working on vaccines that offer broader protection against multiple strains of the virus.

The World Health Organization warned in a news conference that the virus behind the current outbreak, H7N9, is one of the most lethal seen in recent years. There have been 32 reported deaths from this avian influenza virus.

Suresh Mittal, a professor of comparative pathobiology in Purdue's College of Veterinary Medicine, has developed a new vaccination method that incorporates genes from multiple strains of the virus and creates protection that could persist through different mutations, he said.

"Avian influenza viruses are moving targets that rapidly evolve and evade vaccines that are specific to a predicted strain," Mittal said. "We need a vaccine that protects against a spectrum of strains to prepare for a potential pandemic. Such a vaccine may not offer full protection from the strain that pops up, but even partial protection could save lives and buy time to create a more effective vaccine."

Mittal created vaccines for past strains of bird flu and continues to collaborate with the Centers for Disease Control and Prevention.

"The strain responsible for the current outbreak appears not to be easily transmitted from person to person, which occurs effectively in a pandemic situation," he said. "Fortunately, avian influenza in humans tends to replicate deep in the lungs where it can't easily get out through coughing. However, the more people this virus infects, the more chances it has to evolve. It is important to keep a close watch on this outbreak."

The H7N9 is a new strain of avian influenza virus with the potential to infect humans, he said.

Mittal's method uses a harmless adenovirus as a vector to deliver avian influenza virus genes into the body where they create a two-fold immune response of antibody and cell-based protection. The adenovirus vector-infected  host cells produce infleunza proteins that lead to the creation of antibodies and special T-cells primed to kill the virus and any cells infected by it.

Any genes important to avian influenza virus protection can be incorporated into the adenovirus vector, and it can be designed to expose the immune system to  both the surface and internal components of the virus. In this way the immune system can be primed to recognize portions of the virus that predominately remain the same across all strains and those that are more difficult for the virus to change as it adapts to the immune system attack, he said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
Monday, April 04, 2016
Purdue Researcher's New 'Tool for the Organic Chemist Toolbox' Licensed to Sigma-Aldrich
U.S. patent for a safer, easier and "greener" method to incorporate fluorine into organic compounds has been licensed to a subsidiary of Sigma-Aldrich Corporation.
Friday, May 24, 2013
Discovery Points to New Approach to Fight Dengue Virus
Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, suggests new approach for designing vaccines against the aggressive mosquito-borne pathogen.
Monday, April 15, 2013
Researcher Taking Shot at Flu Vaccine That's More Effective, Easier to Make
In the midst of an unusually deadly flu season and armed with a vaccine that only offers partial protection, researcher is working on a flu vaccine that overcomes the need to predict which strains will hit each year.
Monday, February 11, 2013
Scientific News
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!